EP Patent

EP2384746A3 — Dual release oral tablet compositions of dexlansoprazole

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2012-03-07 · 14y expired

What this patent protects

The present invention relates to dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and furthermore directed to processes for the manufacture of the tablet composition and its use in the treatment of gastrointes…

USPTO Abstract

The present invention relates to dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and furthermore directed to processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP2384746A3
Jurisdiction
EP
Classification
—
Expires
2012-03-07
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.